A nal cancer is strongly associated with high-risk (HR) human papillomavirus (HPV) infection and is a common nonacquired immune deficiency syndrome (AIDS)-defining cancer in HIV-infected individuals, despite the widespread use of combined antiretroviral therapy (CART). [1] [2] [3] The standard treatment for invasive anal cancer is a combination of chemotherapy and radiation therapy which is associated with significant immediate and delayed morbidity. 4 A recent meta-analysis of HIV-infected men in the CART era detected a pooled anal cancer rate of 45.9 per 100,000 (95% confidence interval [CI] , 31.2-60.3) 5 with HPV 16 the most frequently detected HR-HPV type (35.4% (95% CI, 32.9-37.9)). The anal cancer rate in HIV-infected women is estimated to be 30 per 100,000 in the United States. 6 Current anal cancer prevention strategies use exfoliative cytology and high-resolution anoscopy (HRA) to diagnose anal high-grade squamous intraepithelial lesions by biopsy (bHSIL), which is then treated to prevent progression to anal cancer. Comprehensive information on the prevalence of any grade of anal SIL in the general population is not currently available. However, in HIV-infected men who have sex with men (MSM), and HIVinfected women the rates of any anal cytological abnormality in recent studies are 47.5% and 39%, respectively. 7, 8 The quadrivalent HPV vaccine (qHPV) (Gardasil; Merck and Co., Kenilworth, NJ) that targets HPV types 6, 11 (low-risk [LR] HPV) and 16, 18 (HR-HPV) is licensed for the prevention of HPV associated anal dysplasia and cancer in both men and women aged 9 to 26 years. In the licensure study of 4065 men aged 16 to 26 years, qHPV was shown to prevent 85.6% (97.5% CI, 73.4-92.9) of persistent qHPV type anal infections in the per protocol analysis of a subset of 602 MSM. 9 The qHPV prevents high-grade squamous intraepithelial lesion (HSIL), the precursor lesion of anal cancer, by preventing persistent infection with HR-HPV types 16 and 18 and is both safe and immunogenic in HIV-infected men and women. [10] [11] [12] More recently, a 9-valent vaccine (9vHPV) (Gardasil; Merck and Co., Kenilworth, NJ) comprising qHPV and 5 additional HR-HPV types (31, 33, 45, 52, and 58) has been approved by the US Food and Drug Administration (FDA).
Oral HPV infection is also more common in HIV-infected than uninfected individuals with reported prevalence rates of 45% in MSM (8% with HPV 16) and 35% in women (5.4% with HPV 16). 13 Similar to the anogenital site, HR-HPV can also cause certain types of oropharyngeal cancer, also with rates higher in HIV-infected individuals than in the general population.
14 A cross-sectional analysis of women exiting a randomized trial of the bivalent (types 16 and 18) HPV vaccine (Cervarix; GlaxoSmithKline, Brentford, UK) suggested vaccine efficacy against oral HPV infection. 15 However, none of the HPV vaccines have an FDA indication for the prevention of HPV-associated oropharyngeal cancer.
The quadrivalent vaccine does not have a US FDA indication for men or women over the age of 26 years, and no US guidelines recommend vaccination in this group. All previous licensure studies of qHPV were performed in men and women with low exposure to HPV based on reports of lifetime number of sexual partners, serological evidence of past HPV infection, and a lower prevalence of HPV and HPV-associated disease. 9, 16, 17 These trials demonstrated high efficacy for prevention of HPV associated disease, but little or no effect on prevelant HPV infection.
To evaluate the potential effect of the quadrivalent vaccine on HIV-infected individuals over age 26 years, a randomized placebo controlled Phase III study of qHPV was conducted. The study aimed to quantify baseline anal, oral and vaginal HPV infection and to report the effect of vaccinating this HIV-1-infected population who were at HR of prior HPV infection to prevent newly acquired persistent infection with qHPV types. Here, we present the baseline information evaluating the prevalence of HPV types and of anal bHSIL in this population.
MATERIALS AND METHODS
Approval was obtained from the AIDS Clinical Trials Group (ACTG) Scientific Agenda Steering Committee, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS, and institutional review board or ethics committees at each participating clinical research site. Written informed consent was obtained from each study participant (ClinicalTrials. gov number NCT01461096).
This multicenter, randomized, double-blinded, placebocontrolled, phase III study was opened at selected ACTG sites (N = 24, 23 domestic US sites with 540 participants and one site in Brazil with 35 participants) with anal cancer screening programs that included capacity for anal cytology, HRA, and ready access to minimally invasive treatments for HSIL, such as topical application of trichloroacetic acid or infrared coagulation. Site clinicians were required to have HRA certification by the AIDS Malignancy Consortium or A5298 study team. The A5298 process included review of training and experience with HRA, and a log of 50 consecutive HRAs that was reviewed by the study team. Satisfactory logs were defined by having adequate lesion descriptions and detection rates of bHSIL. Site clinicians with satisfactory logs underwent a virtual or in-person site visit to assess at least 4 HRA procedures before approval.
Participants were enrolled in two phases, men (target of 464) started enrollment in March 2012 and following a protocol version change; women (target of 100) were enrolled from January 2013 with full enrollment of 575 participants completed in August 2013. Both HIV-infected men and women aged 27 years or older in good general health without a history of invasive or microinvasive cancer at any anal, genital, or oral site were eligible to screen. Men had to report receptive anal sex (defined as a history of receptive penile-anal sex with another man and/or receptive oral-anal sex) within 1 year before entry. Women were required to be on a reliable form of contraception and neither pregnant nor breastfeeding. At least 30% or 140 men were required to have bHSIL as were 50% or 50 of the women to ensure adequate power for the secondary objective of the study assessing the effect of qHPV following treatment of bHSIL. After informed consent, at the screening visit participants had anal and vaginal (in females) swabs (Digene Female Swab Specimen Collection Kit (Catalog Number: 5123-1220); Qiagen, Valencia, CA) taken for HPV DNA, an anal cytology swab, a detailed oral examination, and a Scope (Proctor and Gamble, Cincinnati, OH) oral rinse for HPV DNA. 18 A certified HRA provider performed the screening HRA within 45 days before entry with biopsies of lesions suspicious for either HSIL, low-grade SIL (LSIL), or condyloma. Individuals with current invasive or microinvasive cancer were not eligible. Potential participants were excluded if they had used topical treatments (trichloroacetic acid, podophyllin, imiquimod or similar compounds, topical 5-fluorouracil, sinecatechins, and cidofovir) within 6 months before entry. Additional exclusion criteria included surgical treatment for intra or perianal SIL or condyloma within 6 months before entry, previous receipt of one or more doses of a HPV vaccine, bleeding diathesis, or use of any systemic antineoplastic or immunomodulatory treatments within 45 days before study entry. For women, a gynecologic examination (including exfoliative cervical cytology screening with or without colposcopy) was also required within 45 days before entry.
At a separate enrollment visit participants had an anal HPV swab, vaginal HPV swab (women), collection of serum for HPV antibodies, an oral exam, Scope (Procter and Gamble, Cincinnati, OH) oral rinse, and a whole saliva sample taken for HPV antibodies (specimens stored). These tests were performed 7 days or longer after the screening HPV DNA tests and 14 days or longer after any anal, cervical, vulvar, vaginal, or oral biopsy. Participants were also asked to complete questionnaires addressing the acceptability of all study procedures.
Pathology/Cytology
All cytologies and anal pathologies were evaluated locally in College of American Pathologists accredited cytology/pathology laboratories in the United States, by local standard of care in Brazil, and reported in accordance with the Bethesda 2001 system terminology guidelines. 19 
HPV Detection
The HPV serological testing was performed using competitive Luminex immunoassay (HPV-4 cLIA; Merck Research Laboratories, Boston, MA). Anal, cervical and oral HPV DNA polymerase chain reaction (PCR) testing was performed using L1 consensus primers MY09/MY11/HMB01 and B-globin primers PC04/ GH20. 20 Specimen adequacy was determined by dot blot hybridization and probed with biotin-labeled B-globin and generic HPV probes; B-globin/HPV-positive samples were then genotyped by using a liquid bead microarray assay based on Luminex technology as described elsewhere. 21 The LMBA typing test is a semiquantitative assay used to detect 37 HPV types that include 6, 11, 16, 18, 26, 
Statistical Analysis
Descriptive statistics were used to summarize the study population demographics and the prevalence of abnormal anal cytology, HSIL, and HPV infection. The Wilcoxon rank-sum test was used to compare the differences in absolute CD4 and nadir CD4 T cell counts by bHSIL and by gender. The χ 2 test was used to assess the association between HPV infection and HSIL status (with no adjustment for coinfections) and between HPV infection and gender at birth. The differences in experience and acceptability of the HRA procedure between men and women were assessed via the Wilcoxon rank-sum test. All statistical tests were performed at the 0.05 level without adjustment for multiple comparisons.
RESULTS
Out of 738 participants screened, 575 were enrolled and randomized between March 2012 and August 2013 (Fig. 1) . Four hundred seventy-two (82%) were male and 103 (18%) were female with a median age of 47 years (interquartile range [IQR], 41-53 years). Forty-six percent were white non-Hispanic, 31% were black non-Hispanic, 20% were Hispanic, and 3% were Asian, Pacific Islander, American Indian, Alaskan, or "more than 1 race." The majority (53%) of men were white non-Hispanic, and most women (56%) were black non-Hispanic (Table 1) .
Ninety-eight percent of participants were receiving CART at study entry and the median duration on antiretroviral drugs was 4.9 years (IQR, 2.4-9.9). Human immunodeficiency virus RNA was suppressed at less than 50 copies per mL in plasma in 470 (83%) of participants. The median and nadir absolute CD4 T cell counts were 602 cells/μL (IQR, 436-767) and 255 cells/ μL (IQR, 110-403), respectively. At study entry, 33% had bHSIL. Participants with bHSIL had a lower median absolute and nadir CD4 T cell count and were less likely to have HIV RNA less than 50 copies per mL compared with the no bHSIL group (542 vs 629 cell/μL, P = 0.009, 203 vs 273 cells/μL, P = 0.002, and 143 [79%] vs 327 [85%], respectively) ( Table 1) . Anal cytology results were available in 572 (99.0%) of 575 participants. Abnormal anal cytology was detected in 357 (62%) participants and was more frequent in participants with bHSIL (83% vs 52%) ( Table 2) .
Anal HPV infection with qHPV types was common in this population with 346 (60%) of 574 having detectable infection. There was no significant differences in the prevalence or number of HPV types identified, or in qHPV or 9vHPV types, between men and women ( Table 3 ). The most common HPV type detected was HPV 16 (32%), followed by HPV 6 (25%), HPV 18 (18%) and HPV 11 (13%) ( Table 4 ). The prevalence of 1, 2, 3, and 4 qHPV types was 38%, 17%, 4%, and 1%, respectively. When the additional 5 HR-HPV types of the 9vHPV were considered, 83% of participants had at least one type detected, with prevalence of HR-HPV types 31, 33, 45, 52, and 58 ranging from 13% to 25%. Each of the HR-HPV types in the 9vHPV was significantly associated with the presence of HSIL on biopsy (P values < 0.05) and 95% of participants with bHSIL had 1 or more 9vHPV types detected. We investigated the relationship of bHSIL and nonaccine HR-HPV types (35, 39, 51, 56, 59, 66, 68). We found that types 39, 56, and 68 were also significantly associated with the presence of bHSIL (P < 0.05) (data not shown). Human papillomavirus types 6 and 11 (LR-HPV) were not associated with HSIL (Table 4 ). The prevalence of HSIL was linearly associated with number of HR-HPV types detected from over 20% with one HR-HPV to over 60% with 7 or more HR-HPV types, P < 0.001 by χ 2 test (see supplemental Figure 1 , http:// links.lww.com/OLQ/A212). Demographic and HIV surrogate marker information were not related to the presence of the 7 HR-HPV types (data not shown).
Oral HPV infection with any qHPV type was present in 10% of participants, and 20% with any 9vHPV types. There were 14 (2%), 13 (2%), 27 (5%), and 14 (2%) participants infected with HPV-6, 11, 16, and 18, respectively. Of the 575, 52 (9%) had one qHPV type infection and 8 (1%) had 2 types (Supplemental Table, http://links.lww.com/olq/A208).
Vaginal HPV infection with any qHPV type was present in 44% of the women. There were 9 (9%), 7 (7%), 24 (23%) and 16 (16%) participants infected with HPV-6, 11, 16, and 18, respectively. Of the 103, 34 (33%) had one qHPV type infection and 11 (11%) had two types (Supplemental Table, http://links.lww. com/olq/A209).
The kappa (k) statistic was used to assess concordance of the HPV types observed in the anal, oral, and vaginal samples. There was only slight agreement of qHPV or 9vHPV types observed in the anal and oral samples in men and women (k <0.2). Between the anal and vaginal sites in women, there was fair to moderate (k = 0.37) concordance of qHPV types and fair but not high (k = 0.24) concordance of 9vHPV types. The concordance of qHPV and 9vHPV types observed in the vaginal and oral samples in women was fair (k = 0.21), and similar for 9vHPV.
Serology for HPV types was performed at baseline. In both male and female participants, serology was positive indicating previous infection with qHPV types 6, 11, 16, and 18 in 62.5%, 41.5%, 47.5%, and 32.0%, respectively (data not shown).
Approximately 50% of participants experienced their first HRA in the context of this trial including 50% of the men and 71% of the women. There was no difference in HRA acceptability between the genders (P = 0.24) (Supplemental Table, http://links. lww.com/olq/A210). The majority (median, >80%) of all participants tolerated all procedures and would be very likely (median, >70%) to recommend anal cancer screening to others (data not shown).
DISCUSSION
In this unvaccinated population of men and women older than 26 years with predominantly well-controlled HIV infection on CART, abnormal anal cytology and anal HPV infection was highly prevalent, with detection of HR-HPV vaccine types significantly correlated with detection of HSIL on anal biopsy.
The HPV prevalence rates were higher than those found in previous observational studies and may be related to several factors including; optimization of sampling at two distinct time points from each anatomical site with data pooling, a median participant age of 47 years, and high prevalence of HPVantibodies, indicating high levels of previous sexual HPV exposure and infection. Additionally, although HPV detection may be transient in the anal canal, it is likely that there was ongoing sexual exposure and infection at the time of screening. Human papillomavirus type 16 was the most common type detected in this and other studies, although at a lower level in men than in a previous metaanalysis. 5, 22 Despite the high HPV prevalence it was initially encouraging that only 5 participants had all 4 qHPVs detected in the anal canal, and had the theoretical potential for some degree of protection with the vaccine. One participant had all 9vHPV types detected.
The connection between immunosuppression, and HPVassociated squamous cell carcinomas has been established in HIVinfected individuals, particularly with CD4 T cells less than 200 cells/mm 3 . 23, 24 In our study, a low nadir CD4 count was associated with the presence of bHSIL lending support to the opinion that once HPV infection is established, the effect of immune reconstitution on HPV clearance is minimal. Most participants in our study were virologically suppressed, but lower rates of current suppression were seen in those individuals with bHSIL. There is accumulating evidence that virological suppression may be important in the control of HPV-related disease and that the cumulative viral load, a measure of longer term HIV exposure, may be associated with an increased incidence of anal cancer. 25 This is supported by the observation that early initiation of antiretroviral therapy, which is now widely recommended, is associated with a reduced risk of virally mediated cancers. 26 Abnormal anal cytology was highly prevalent, with atypical squamous cells of undetermined significance and LSIL comprising the majority of cytological abnormalities. We observed a sensitivity and specificity of abnormal anal cytology for bHSIL of 83% and 47%, respectively. Although this study used a noncommercial PCR-based HPV detection test which is not currently approved by the FDA, pairing anal cytology with FDA approved, commercially available HR HPV testing may improve test characteristics similar to current cervical cytology screening algorithms. It is of interest that the number of HR-HPV vaccine types detected was significantly associated with bHSIL at the time of HRA. It may be feasible to use HR-HPV testing as the initial screening test to determine who should proceed to HRA, especially when using HPV tests with typing information that includes non-9vHPV HR types also associated with cytological abnormalities and bHSIL.
The study limitations in part relate to the prestipulated requirements for 50% of female participants to have bHSIL, and following full accrual of the non-bHSIL group 15 female participants were excluded without bHSIL. For men, it was required that 30% have bHSIL, but no male participants were excluded for this reason. This prevents estimation of HSIL prevalence in HIV-infected women. However, this limitation does not affect predictors of HSIL. We did not require a minimum number of anal biopsies, or random biopsies if no visible HSIL was detected as has been done in some studies, so despite provider certification in the HRA procedure, HSIL may have been missed at baseline. Furthermore, a central pathology review was not used to verify local anal pathology diagnoses, although all sites except Brazil had College of American Pathologists accreditation, and we did not type HSIL histology specimens to determine the associated HPV type. Despite the established increased risk of anal cancer in both HIV-infected men and women, 6 there are a limited number of centers with expertise in screening, diagnosis and minimally invasive treatment of HSIL. This study demonstrates that even in a cohort enriched with individuals with a higher prevalence of HR HPV infection, detection of HR HPV increases the risk for detecting prevalent bHSIL. Future studies should evaluate the role of HPV testing, especially those providing typing information in anal cancer screening algorithms to focus HRA on those at highest risk. Primary prevention with the 9vHPV vaccine is critical for preventing anal HSIL and cancer, especially in areas where anal cancer screening services are limited and in areas with high HIV incidence. 
